

# Schriftenverzeichnis Prof. Dr. med. Johannes Ruef

## I Originalarbeiten

- 1) Bode C, Nordt T, Freitag M, **Ruef J**, Kaltenmeier M, Meinhardt G, Kübler W, Haber E. Verstärkte Thrombolyse und verminderte Thrombozytenaggregation durch ein anti-GPIIb/IIIa-Antikörper Urokinase Hybridmolekül (7E3-UK). Verh Dtsch Ges Inn Med 1991, 97:1-2.
- 2) Bode C, **Ruef J**, Freitag M, Harker LA, Runge MS. Thrombolytische und antithrombotische Eigenschaften eines rekombinanten Prourokinase-antifibrin Hybridmoleküls in Primaten. Zeitschrift für Kardiologie 1993; 82: 136.
- 3) Runge MS, Harker LA, Bode C, **Ruef J**, Kelly AB, Marzec UM, Allen E, Caban R, Shaw S-Y, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996; 94: 1412-1422.
- 4) Bode C; Peter K, Nordt TK, **Ruef J**, Smalling RW, Kübler W. Pharmacology and clinical efficacy of reteplase. Fibrinolysis and Proteolysis 1997; 11 (Suppl. 2): 29-33.
- 5) **Ruef J**, Hu ZY, Yin L-Y, Hanson SR, Kelly AB, Harker LA, Rao GN, Runge MS, Patterson C. Induction of vascular endothelial growth factor in balloon-injured baboon arteries: a novel role for reactive oxygen species in atherosclerosis. Circulation Research 1997; 81: 24-33.
- 6) **Ruef J**, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A, Runge MS. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation 1998, 97: 1071-1078.
- 7) Wu Y, **Ruef J**, Rao GN, Runge MS, Patterson C. Differential transcriptional regulation of the human thrombin receptor gene by the SP family of transcription factors in human endothelial cells. Biochem J. 1998; 330: 1469-1474.
- 8) Gowda A, Yang C, Asimakis GK, **Ruef J**, Rastegar S, Runge MS, Motamedi M. Cardioprotection by local heating: improved myocardial salvage after ischemia and reperfusion. Ann Thorac Surg 1998, 65: 1241-1247.
- 9) **Ruef J**, Papadaki M, Nguyen TK, Patterson C, Eskin SG, McIntire LV, Runge MS. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. Circulation Research, 1998, 83: 1027-1034 (2 Erstautoren).

- 10) Nordt TK, Moser M, Kohler B, **Ruef J**, Peter K, Kübler W, Bode C. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. *Thromb Haemost* 1998; 80: 881-886.
- 11) **Ruef J**, Lighezan R, Schuler G, Nordt TK, Kübler W, Bode C. Ticlopidine versus Phenprocoumon in Patients with Palmaz-Schatz Coronary Stent: Occlusion Rates and Markers of Hemostatic Activation. *Fibrinolysis & Proteolysis* 1999; 13: 124-132.
- 12) **Ruef J**, Patterson C, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47phox may participate in forming this oxidase in vitro and in vivo. *J Biol Chem* 1999; 274: 19814-19822 (2 Erstautoren).
- 13) **Ruef J**, Nordt TK, Peter K, Runge MS, Kübler W, Bode C. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation. *Thrombosis Haemostasis*, 1999, 82: 109-114.
- 14) **Ruef J**, Meshel AS, Hu Z, Horaist C, Ballinger C, Thompson LJ, Subbarao VD, Dumont JA, Paterson C. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation in vivo after carotid injury in the rat. *Circulation* 1999, 100: 659-665.
- 15) Moser M, Nordt T, Peter K, **Ruef J**, Kohler B, Schmittner M, Smalling R, Kübler W, Bode C. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. *Circulation* 1999, 100: 1858-1864.
- 16) **Ruef J**, Liu S-Q, Bode C, Tocchi M, Srivastava s, Runge MS, Bhatnagar A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation following arterial injury. *Arterioscl Thromb Vascul Biol* 2000, 20: 1745-1752.
- 17) Peter K, Kohler B, Straub A, **Ruef J**, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine. Continuous platelet inhibition by the combination of abciximab and ticlopidine. *Circulation* 2000, 102: 1490-1496.
- 18) **Ruef J**, Kacharava A, Pohl J, Bode C, Runge MS. Indications for the presence of an atypical protease-activated receptor (PAR) on rat platelets. *Ann Hematol* 2000, 79: 604-611.
- 19) **Ruef J**, Moser M, Bode C, Kübler W, Runge MS. 4-Hydroxynonenal induces apoptosis, NF- $\kappa$ B activation and formation of 8-isoprostane in vascular smooth muscle cells. *Basic Res Cardiol* 2001, 96: 143-150.

- 20) Bhatnagar A, **Ruef J**, Liu S, Srivastava S, Srivastava SK. Regulation of vascular smooth muscle cell growth by aldose reductase. *Chem Biol Interact* 2001, 130-132: 627-636.
- 21) The GUSTO V investigators (coauthor: **Ruef J**). Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. *The Lancet* 2001; 357: 1905-1914.
- 22) Nordt TK, Lutzi S, **Ruef J**, Peter K, Klar E, Kübler W; Sobel BE, Bode C. Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells. *Thrombosis & Haemostasis*, 2001; 86: 1305-1313.
- 23) Moser M, **Ruef J**, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C. Ecarin Clotting Time but not aPTT Correlates with PEG-Hirudin Plasma Activity. *J. Thrombosis and Thrombolysis* 2001; 12: 165-169.
- 24) **Ruef J**, Moser M, Kübler W, Bode C. Induction of Endothelin-1 Expression by Oxidative Stress in Vascular Smooth Muscle Cells. *Cardiovasc Pathol* 2001; 10: 309-313.
- 25) Bekeredjian R, Behrens S, **Ruef J**, Dinjus E, Unger E, Baum M, Kuecherer H. Potential of gold-bound microtubules as a new ultrasound contrast agent. *Ultrasound Med Biol* 2002; 28: 691-695.
- 26) Bertram U, Moser M, Peter K, Kuecherer H, Bekeredjan R, Straub A, Nordt TK, Bode C, **Ruef J**. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions. *J Thromb Thrombolysis*. 2002; 14: 197-203.
- 27) Madamanchi NR, Hu ZY, Li F, Horaist C, Moon SK, Patterson C, Runge MS, **Ruef J**, Fritz PH, Aaron J. A noncoding RNA regulates human protease-activated receptor-1 gene during embryogenesis. *Biochim Biophys Acta*. 2002; 1576: 237-245. Erratum in: *Biochim Biophys Acta*. 2003; 1626: 106.
- 28) Moser M, Bertram U, Peter K, Bode C, **Ruef J**. Abciximab, eptifibatide, and tirofiban exhibit dose dependent potencies to dissolve platelet aggregates. *J Cardiovasc Pharm* 2003; 41: 586-592.
- 29) Haase J, Bayar R, Hackenbroch M, Störger H, Hofmann M, Schwarz C-E, Reinemer H, Schwarz F, **Ruef J**, Sommer T. Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers and time to intervention. *J. Interventional Cardiology* 2004, 17: 367-373.
- 30) Hofmann M, Stoerger H, Schwarz F, Schwarz C-E, Reinemer H, **Ruef J**, Schoepf J, Haase J. Percutaneous saphenous vein graft interventions with and without distal filter wire protection. *J. Interventional Cardiology* 2005, 18: 475-480.
- 31) Kranzhöfer R, **Ruef J**. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the  $PLA_{1/2}$  polymorphism. *Platelets* 2006; 17: 163-169.

- 32) **Ruef J**, März W, Winkelmann B. Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. *Scand Cardiovasc J* 2006; 40: 274-279.
- 33) **Ruef J**, Hofmann M, Haase J. Initial clinical experience with the Protégé EverFlex™ long self-expanding nitinol stent in the superficial femoral artery. *J Interv Cardiol* 2006; 19: 544-546.
- 34) **Ruef J**, Kranzhöfer R. Coronary stent thrombosis related to aspirin resistance. What are the underlying mechanisms? A case report. *J Interv Cardiol* 2006; 19: 507-509.
- 35) **Ruef J**, Hofmann M, Störger H, Haase J. Four-year results after brachytherapy for diffuse coronary in-stent restenosis. Will coronary brachytherapy survive? *Cardiovasc Revasc Med* 2007; 8: 170-174.
- 36) **Ruef J**, Browatzki M, Pfeiffer CAH, Schmidt J, Kranzhöfer R. Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2. *Vasc Med* 2007, 12: 23-27.
- 37) Störger H, **Ruef J**. Closure of guide-wire induced coronary artery perforation with a two-component fibrin glue. *Catheter Cardiovasc Interv* 2007; 70: 237-240.
- 38) Günther J, Marrouche N, **Ruef J**. Ablation of atrial flutter by the femoral approach in the absence of inferior vena cava. *Europace* 2007; 9: 1073-1074.
- 39) **Ruef J**, Störger H, Schwarz F, Haase J. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. *Catheter Cardiovasc Interv* 2008; 71: 333-339.
- 40) **Ruef J**, Kuehnl P, Meinertz T, Merten M. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation. *Platelets* 2008; 19: 359-364.
- 41) **Ruef J**. One year follow-up after implantation of the EverFlex™ nitinol stent in long lesions of the superficial femoral artery. *Angiology* 2009, 60: 31-35.
- 42) Bosiers M, Torsello G, Gissler HM, **Ruef J**, Müller-Hülsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroë H, Mathias K, Koppensteiner R, Vermassen F, Scheinert D. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. *J. Endovasc. Ther.* 2009; 16: 261-269.
- 43) Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KA, Goldberg RJ, Anderson FA Jr; Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators (Co-Investigator: **Ruef J**). The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. *Am. Heart J.* 2009; 158: 193-201.
- 44) **Ruef J**, Störger H, Schwarz F, Haase J. Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-Choice stent compared to the paclitaxel-eluting TAXUS stent. *Clinical Cardiology*; 2010; 33: E33-38.

## II Übersichtsarbeiten

- 1) Bode C, Nordt T, **Ruef J**, Kübler W. Optimierung der thrombolytischen Therapie des akuten Myokardinfarktes- neue Thrombolytika und Antithrombotika. Münchn. Med. Wochenschrift 1994; 136: 524-528.
- 2) Bode C, Peter K, Nordt T, Kohler B, Moser M, **Ruef J**, Runge MS. New developments in thrombolytic therapy. Fibrinolysis & Proteolysis 1997; 11 (Suppl 1): 109-114.
- 3) Bode C, Moser M, **Ruef J**, Nordt T, Peter K, Kübler W, Smalling RW. Clinical studies with reteplase. Drugs of Today 1997; 33: 649-653.
- 4) Bode C, Nordt TK, Peter K, **Ruef J**, Runge MS, Kübler W. Targeting of thrombolytic and antithrombotic agents. Fibrinolysis and Proteolysis 1997; 11 Suppl. 2: 63-70.
- 5) **Ruef J**, Bode C, Runge MS. Effects of fluid shear stress on hemostasis and atherosclerosis. Fibrinolysis & Proteolysis 1997; 11: Suppl. 2: 159-164.
- 6) **Ruef J**, Peter K, Nordt TK, Kübler W, Bode C. Die Bedeutung von oxidativem Streß in der Atherogenese. Kardiovaskuläre Medizin/German Journal of Cardio-Vascular Medicine 1999; 3: 4-12.
- 7) **Ruef J**, Peter K, Nordt TK, Runge MS, Kübler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thrombosis & Haemostasis, 1999, 82 (Suppl.) 32-37.
- 8) Peter K, Weirich U, Nordt TK, **Ruef J**, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thrombosis & Haemostasis, 1999, 82 (Suppl.) 38-43.
- 9) Nordt TK, Peter K, **Ruef J**, Kübler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thrombosis & Haemostasis, 1999, 82 (Suppl.) 14-18.
- 10) Papadaki M, Eskin SG, **Ruef J**, Runge MS, McIntire LV. Fluid shear stress as a regulator of gene expression in vascular cells: possible correlations with diabetic abnormalities. Diabetes Research and Clinical Practice, 1999, 45: 89-99.
- 11) **Ruef J**, Nordt TK, Bode C. Die medikamentöse Therapie des akuten Koronarsyndroms: Bewährtes und neue Entwicklungen. Arzneimitteltherapie 2002; 2: 47-54.

- 12) **Ruef J**, Katus HA. New antithrombotic drugs on the horizon. *Expert Opin Investig Drugs* 2003, 12: 781-797.
- 13) **Ruef J**. Antikoagulation: Bewährtes und neue Trends im Überblick. *Kliniker* 2003, 8: 258-264.
- 14) **Ruef J**, Katus HA. Venöse Thrombose und Thrombophilie – Management von Prophylaxe und Therapie. *Hämostaseologie* 2003, 23: 186-198.
- 15) **Ruef J**. New antithrombotic drugs - advantages to conventional treatment. *European J Hospital Pharmacists* 2003; 5: 11-12.
- 16) **Ruef J**. Beeinflussen Statine die Effekte antithrombotischer Pharmaka? *Medizinische Klinik* 2004, 99: 22-27.
- 17) **Ruef J**, Hofmann M, Haase J. Endovascular interventions in iliac and infrainguinal occlusive artery disease. *J. Interventional Cardiology* 2004, 17: 427-435.
- 18) **Ruef J**. Interaktionen von Statinen mit antithrombotischen Substanzen. *Internist. Prax.* 2005; 45: 603-611.
- 19) **Ruef J**. Interaktionen von Statinen mit antithrombotischen Substanzen. *Arzneim.-, Therapie-Kritik* 2005; 37: 225-233.
- 20) **Ruef J**. Ambulante Diagnostik und Therapie der tiefen Venenthrombose. *PantaRei - alles im Fluss* 2006; 10: 6-9.
- 21) Klingenberg T, **Ruef J**, Hammerstingl C. Medikamentöse Rhythmuskontrolle und orale Antikoagulation bei Patienten mit Vorhofflimmern: Bedeutung pharmakokinetischer Interaktionen für die klinische Praxis. *Aktuelle Kardiologie* 2015; 4:114-119.

### III Buchbeiträge

- 1) Bode C, Nordt T, Freitag M, **Ruef J**, Kaltenmeier M, Meinhardt G, Kübler W, Haber E. Verstärkte Thrombolyse und verminderte Thrombozytenaggregation durch ein anti-GP IIb/IIIa Antikörper Urokinase Hybridmolekül (7E3-UK). In: *Verhandlungen der Deutschen Gesellschaft für Innere Medizin*; Editor: Miehle K. Springer Verlag 1991: 1-2.
- 2) Bode C, Nordt T, **Ruef J**, Kohler B, Peter K, Katus HA. Differenzierte thrombolytische Therapie des akuten Myokardinfarktes. In: *Thrombolyse und Antikoagulation in der Kardiologie*. Eds: Hach-Wunderle V, Neuhaus KL. Springer Verlag 1994: 49-60.
- 3) **Ruef J**, Bode C, Runge MS. An aldehydic lipid peroxidation product induces redox-sensitive vascular smooth muscle cell growth. *Proceedings of the XIII. World Congress of Cardiology, International Proceedings Division*, Monduzzi Editore, 1998: 1147-1150.

4) **Ruef J**, Bode C. Thrombolyse des akuten Myokardinfarktes und antithrombotische Therapie zur Prophylaxe ischämischer Komplikationen nach Thrombolyse und PTCA. In: Rostocker Symposien (Thrombophilie und hämorrhagische Diathesen). Weller Verlag 1999; S. 85-99.

5) **Ruef J**, Katus HA. Thrombophilie – Diagnostik und therapeutische Konsequenzen. In: Life-Style & Anti-Aging-Medizin. Hrsgb. Rabe T, Strowitzki T; 2002, Rendezvous Verlag Baden-Baden (ISBN: 3-936881-00-6).

6) **Ruef J**. Eigenschaften klassischer und neuer Thrombolytika. In: Thrombolysetherapie bei arteriellen und venösen Akuterkrankungen, Deutscher Ärzteverlag Köln, 2005.